Literature DB >> 9581441

Race and the treatment of cytomegalovirus retinitis in a cohort of patients with acquired immunodeficiency syndrome.

A K Wutoh1, J Hidalgo, J Bareta, W Rhee, R Beardsley, S Steidl.   

Abstract

This historical cohort study assessed the impact of race on critical factors in the diagnosis and drug treatment of cytomegalovirus (CMV) retinitis in acquired immunodeficiency syndrome (AIDS) patients over a 7-year period. The study subjects included 194 adult patients with a history of AIDS who were treated for CMV retinitis between September 1987 and September 1994. Abstracted inpatient hospital medical records and a statewide automated AIDS database were the primary sources of data. Patients were assessed for severity of CMV retinitis at diagnosis, time from initial CMV retinitis diagnosis to first treatment, survival from diagnosis of AIDS, and initiation of drug treatment for CMV retinitis. Results indicated a significant difference in the severity of CMV retinitis at diagnosis by race. Patients diagnosed with early disease were more likely to be white, whereas patients diagnosed with severe disease were more likely to be black. There was no difference in the type of CMV retinitis treatment or patient survival time after diagnosis, nor time to treatment once diagnosed by race. These results suggest that differences in survival may not be the result of discrimination against black patients and may be due more likely to practices associated with accessing medical treatment.

Entities:  

Mesh:

Year:  1998        PMID: 9581441      PMCID: PMC2568231     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  13 in total

Review 1.  Overview of cytomegalovirus infections in HIV-infected patients: current therapies and future strategies.

Authors:  C S Crumpacker; M Heath-Chiozzi
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1991

Review 2.  Minority AIDS prevention: moving beyond cultural perspectives towards sociopolitical empowerment.

Authors:  V De La Cancela
Journal:  AIDS Educ Prev       Date:  1989

3.  Race, ethnicity, and access to ambulatory care among US adolescents.

Authors:  T A Lieu; P W Newacheck; M A McManus
Journal:  Am J Public Health       Date:  1993-07       Impact factor: 9.308

4.  Cytomegalovirus retinitis and acquired immunodeficiency syndrome.

Authors:  D A Jabs; C Enger; J G Bartlett
Journal:  Arch Ophthalmol       Date:  1989-01

5.  Zidovudine and the natural history of the acquired immunodeficiency syndrome.

Authors:  R D Moore; J Hidalgo; B W Sugland; R E Chaisson
Journal:  N Engl J Med       Date:  1991-05-16       Impact factor: 91.245

6.  Race, sex, drug use, and progression of human immunodeficiency virus disease.

Authors:  R E Chaisson; J C Keruly; R D Moore
Journal:  N Engl J Med       Date:  1995-09-21       Impact factor: 91.245

7.  Racial differences in the use of drug therapy for HIV disease in an urban community.

Authors:  R D Moore; D Stanton; R Gopalan; R E Chaisson
Journal:  N Engl J Med       Date:  1994-03-17       Impact factor: 91.245

8.  HIV-1 seroprevalence and risk behaviors in an urban African-American community cohort.

Authors:  A F Brunswick; A Aidala; J Dobkin; J Howard; S P Titus; J Banaszak-Holl
Journal:  Am J Public Health       Date:  1993-10       Impact factor: 9.308

9.  Survival differences in patients with AIDS.

Authors:  G H Friedland; B Saltzman; J Vileno; K Freeman; L K Schrager; R S Klein
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1991

10.  Zidovudine therapy and health resource utilization in AIDS.

Authors:  R D Moore; J Hidalgo; J C Bareta; R E Chaisson
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1994-04
View more
  2 in total

Review 1.  Race and racialism in scientific research and publication in the Journal of the National Medical Association.

Authors:  O Odocha
Journal:  J Natl Med Assoc       Date:  2000-02       Impact factor: 1.798

2.  Relationship Between Opacity of Cytomegalovirus Retinitis Lesion Borders and Severity of Immunodeficiency Among People With AIDS.

Authors:  Gary N Holland; Mark L Van Natta; David T Goldenberg; Rory Ritts; Ronald P Danis; Douglas A Jabs
Journal:  Invest Ophthalmol Vis Sci       Date:  2019-05-01       Impact factor: 4.799

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.